drugset / Trial / NCT04385199

Convalescent Plasma for Patients With COVID-19

NCT04385199

Phase 2 Completed 30 enrolled Henry Ford Health System
RandomizedParallel-groupOpen-labelTreatment

Summary

Pilot study of tolerability and efficacy of transfusion of 200mL of convalescent plasma in patients with COVID-19 respiratory disease.

Timeline

Start
2020-05-04
Primary completion
2020-08-01
Completion
2020-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Convalescent Plasma Protein / enzyme biologic 200 ml Other

Indications